- Residency - Montefiore Med. Ctr. & Albert Einstein College of Med. (2007-2011), Radiation Oncology
- Internship - SUNY Downstate Medical Center (2006-2007), Internal Medicine
- Medical School - SUNY Downstate Medical Center (2002-2006)
- Graduate School - SUNY Downstate Medical Center (1999-2002)
Raquibul Hannan, M.D., Ph.D.
- Radiation Oncology
- Radiation Therapy for Prostate Cancer
- Radiation Therapy for Genitourinary Cancer
Raquibul Hannan, M.D., Ph.D., became fascinated with cancer as an undergraduate at New York University. His curiosity led him to pursue a combined medical degree and Ph.D. at State University of New York at Brooklyn from 1999 to 2006. For his Ph.D. research he worked on the immunology of pancreatic carcinogenesis and discovered a novel marker for pancreatic cancer. Following a medical internship the next year, he completed his residency in radiation oncology at Montefiore Medical Center and Albert Einstein College of Medicine in 2011.
Then, he became a Texan. Dr. Hannan is now Associate Professor of Radiation Oncology at UT Southwestern Medical Center. He specializes in radiation treatment of genitourinary (GU) cancers including prostate, kidney, bladder, penile, testicular, and ureteral cancer.
Dr. Hannan is knowledgeable in a range of radiation techniques including IMRT, IGRT, linac-based SRS, SBRT, and intracavitary and interstitial brachytherapy.
As an expert in these areas as well as a leading young researcher on the topic of immunologic effects of radiation treatment and immunotherapy in general, he holds two international patents and has presented his findings at symposiums and conferences around the world.
Dr. Hannan is a member of a number of professional organizations including the American Society of Radiation Oncology (ASTRO), the American Board of Radiology (ABR), the American College of Radiology (ACR), the Radiological Society of North America (RSNA), and the American Society of Clinical Oncology (ASCO).
Meet Dr. Hannan
Dallas Radiation Oncologist
What if the body’s own immune system could fight off cancer? How does radiation treatment affect the patient’s immune response to cancer? These have been particular areas of interest and research for Associate Professor of Radiation Oncology Raquibul Hannan, M.D., Ph.D. As a board-certified radiation oncologist and an expert in radiation therapy for patients with genitourinary cancer, he feels research into strategies for combining immunotherapy with radiation therapy is an effective means of maximizing the treatment outcome for his patients.
"One of the motivations I have in doing translational research is to improve my patients’ cancer outcome. I will go out of my way to make sure the patient is getting the right treatment and whatever is best for his or her outcome.”
Genitourinary cancers include prostate, kidney, bladder, penile, testicular, and ureteral cancer. External beam radiation, including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiation therapy (SBRT), typically plays a key role in the treatment of these cancers. As a scientist, Dr. Hannan is exploring strategies of combining immunotherapy with radiation therapy. As a physician, he will do whatever it takes to make sure a patient is getting the right treatment and achieving the best outcome possible.
State-of-the-art technology in radiation equipment and a cutting-edge scientific environment drew Dr. Hannan to UT Southwestern Medical Center. The latest technology makes a big difference in caring for patients, he says. “The better the technology, the more precise the delivery of radiation, which spares the normal structures and eradicates the tumor,” he says.
- American Society of Therapeutic Radiology and Oncology
- American Society of Clinical Oncology
- International Patent 2005, Pancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods
- US Patent 2006, Pancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods Development of a PaCa-Ag1-Specific Enzyme-Linked Immuno-Assay
- Radiation and Cancer Biology Poster Award 2010, ASTRO 52nd Annual Meeting
Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.
Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, Guha C Cancer immunology, immunotherapy : CII 2012 Dec 61 12 2227-38
Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK Practical radiation oncology 2014 4 6 409-14
Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L, Kim DN, Hannan R, Watumull LM, Brugarolas J Clinical genitourinary cancer 2014 Dec
Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.
Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn CG, Choe KS, Kim DN Cancer biology & therapy 2014 Mar 15 6
Stereotactic Radiation Therapy of Renal Cancer Inferior Vena Cava Tumor Thrombus.
Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky A, Pedrosa I, Choy H, Brugarolas JB, Timmerman RD Cancer biology & therapy 2015 Mar 0
A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases.
Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R Annals of surgical oncology 2015 May
Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy.
Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D Cancer medicine 2015 Oct
Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R European journal of cancer (Oxford, England : 1990) 2016 May 59 142-51
Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF.
Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R Proceedings of the National Academy of Sciences of the United States of America 2016 Sep
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, Laine A, Xie XJ, Choy H, Brugarolas J, Timmerman R, Hannan R International journal of radiation oncology, biology, physics 2017 May 98 1 91-100
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.
Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R Oncoimmunology 2018 7 7 e1440168
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.
Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J Cancer discovery 2018 Jun
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX The Journal of clinical investigation 2018 Feb 128 2 580-588
Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Brugarolas J, Timmerman R, Hannan R, International journal of radiation oncology, biology, physics 2019 Jul
- Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.
- Investigate strategies to combine immunotherapy with SAbR (i-SAbR) for cancer treatment
- Innate and adaptive immune responses generated by tumor irradiation with stereotactic ablative radiotherapy (SAbR)
- Improve cancer patient treatment outcome through the design of i-SAbR clinical trials
- Radiation Therapy for Prostate Cancer
- Radiation Therapy for Genitourinary Cancer
- Radiation Therapy for Testicular Cancer
- Radiation Therapy for Bladder Cancer
- Radiation Therapy for Kidney Cancer